Soleno Therapeutics (SLNO) Retained Earnings (2013 - 2026)
Soleno Therapeutics (SLNO) reported Retained Earnings of -$400.0 million for Q1 2026, up 19.35% year-over-year from -$335.1 million in Q1 2025, and down 96485.54% quarter-over-quarter from $415000.0 in Q4 2025.
Soleno Therapeutics (SLNO) Retained Earnings (2013 - 2026) Analysis & Trends
Soleno Therapeutics (SLNO) has 14 years of Retained Earnings data on file, last reported at -$400.0 million in Q1 2026.
- Retained Earnings for Q1 2026 came in at -$400.0 million, up 19.35% year-over-year; the trailing twelve-month figure through Mar 2026 was -$400.0 million (up 19.35% YoY), and the FY2025 annual result was $415000.0, up 100.09% from the prior year.
- Retained Earnings fell to -$400.0 million in Q1 2026 per SLNO's latest filing, from $415000.0 in the prior quarter.
- Over five years, Retained Earnings peaked at $415000.0 in Q4 2025 and troughed at -$500.7 million in Q2 2025.
- A 5-year average of -$252.2 million and a median of -$254.3 million in 2023 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2023 and 2025: Retained Earnings plunged 13254900.0% in 2023, then jumped 100.09% in 2025.
- A 5-year view of Retained Earnings shows it stood at -$237.4 million in 2022, then declined by 16.42% to -$276.4 million in 2023, then tumbled by 63.62% to -$452.3 million in 2024, then jumped by 100.09% to $415000.0 in 2025, then sank by 96485.54% to -$400.0 million in 2026.
- Business Quant data shows SLNO's Retained Earnings at -$400.0 million in Q1 2026, $415000.0 in Q4 2025, and $360000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | -153.89 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -211.85 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 1.00 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 130.89 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -279.00 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.88 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 14.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -838.07 Mn |
| 10 | Soleno Therapeutics | 2.76 Bn | 2.51 Bn | 93.41 Mn | -400.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -400.00 Mn |
| Dec 31, 2025 | 415,000.00 |
| Sep 30, 2025 | 360,000.00 |
| Jun 30, 2025 | -500.74 Mn |
| Mar 31, 2025 | -496.00 Mn |
| Dec 31, 2024 | -452.26 Mn |
| Sep 30, 2024 | -396.30 Mn |
| Jun 30, 2024 | -319.70 Mn |
| Mar 31, 2024 | -106,000.00 |
| Dec 31, 2023 | -276.41 Mn |
| Sep 30, 2023 | -265.10 Mn |
| Jun 30, 2023 | -254.25 Mn |
| Mar 31, 2023 | -245.80 Mn |
| Dec 31, 2022 | -237.42 Mn |
| Sep 30, 2022 | -2,000.00 |
| Jun 30, 2022 | -225.80 Mn |
| Mar 31, 2022 | -219.08 Mn |
| Dec 31, 2021 | -213.36 Mn |
| Sep 30, 2021 | -210.53 Mn |
| Jun 30, 2021 | -202.39 Mn |